VAXART INC. - COMMON STOCK

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

14 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

07 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

06 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

05 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

19 1 2024 08:30:00 提供 Nasdaq GlobeNewswire

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

16 1 2024 09:25:20 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Announces Management Change

16 1 2024 09:22:58 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

29 12 2023 11:12:33 提供 NetDania Notify

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

21 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

02 11 2023 16:01:22 提供 Nasdaq GlobeNewswire

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

02 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

26 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

11 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

21 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

06 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

03 8 2023 16:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

27 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

06 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

26 6 2023 16:45:00 提供 Nasdaq GlobeNewswire

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

21 6 2023 16:30:00 提供 Nasdaq GlobeNewswire